Technavio predicts the global peripheral neuropathy treatment market to post a CAGR of close to 4% by 2022 (Graphic: Business Wire)
The global peripheral neuropathy treatment market 2018-2022 is expected to post a CAGR of close to 4% during the forecast period, according to the latest market research report by Technavio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181016005698/en/
Technavio predicts the global peripheral neuropathy treatment market to post a CAGR of close to 4% by 2022 (Graphic: Business Wire)
A key factor driving the growth of the market is the rising awareness of peripheral neuropathy. Peripheral neuropathy is often misdiagnosed due to its complex array of symptoms. A major challenge associated with peripheral neuropathy is that this condition is usually painless, and patients look for medical help only when the pain starts, which is at a much later stage. Peripheral neuropathy is recognized as the most frequent cause of non-traumatic amputation in diabetic patients. The Neuropathy Association creates awareness of peripheral neuropathy by providing patients with the necessary resources, information, and tools to deal with the disease.
This market research report on the global peripheral neuropathy treatment market 2018-2022 also provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Technavio classifies an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
In this report, Technavio highlights the increase in the number of biologics in the drug development pipeline as one of the key emerging trends in the global peripheral neuropathy treatment market:
Global peripheral neuropathy treatment market: Increase in the number of biologics in the drug development pipeline
Biologics are pharmaceutical drug products synthesized from various biological sources. These are different from chemically synthesized pharmaceuticals. They include vaccines, blood, blood components, monoclonal antibodies, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and the living cells used in cell therapy.
“The drugs made of biologics can be administered either as monotherapy or as a combination therapy. Currently, all the approved drugs for peripheral neuropathy are small molecules. However, with the rapid technological advances in the pharmaceutical sector, biologics are being developed aiming at the permanent cure of peripheral neuropathy,” says a senior analyst at Technavio for research on infectious and rare diseases.
Global peripheral neuropathy treatment market: Segmentation analysis
This market research report segments the global peripheral neuropathy treatment market by subtype (diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, and others) and geographical regions (APAC, EMEA, and the Americas).
The Americas led the market in 2017 with a market share of more than 41%, followed by APAC and EMEA respectively. The region is expected to continue to dominate the market during the forecast period.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation
Geographical Segmentation
Market Drivers
Market Challenges
Market Trends
Vendor Landscape
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181016005698/en/
Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com